This dashboard serves as an interactive platform for the Genomic Pioneer members. Over a period of time we can reflect back on the threads to perhaps review how the field of genomics is shaping up through our eyes. That will be interesting to see!
You do not need any sign up or give any personal information. Just pick a screen name and start typing! What are you waiting for? Get started:) Just remember this URL to come back again.

http://etherpad.com/roT866i6Ls

Some ideas to use this dashboard:

* Introducing ourselves and share interesting information about our interests, findings, anything scientific really!
* Rate interesting genomics papers and share it with the users.
* Share/Review interesting papers and stuff you came across.
* Share information and get feedback on your work
* Share and rekindle classic science which has got lost over the years
* Start a debate on a burning topic of interest!
* We will also use this platform to hold interactive sessions with key thought leaders and use it for our regular -OMICs Saturday chats!
*You can also talk live to other genomics folks online.

Any more ideas Pioneers?

cheers,
Ashwin

Recently, Dr.Ron Hencin, VP, BioResearch Sales, talked with Pharma Services News (BioITworld) editor John Russell about Gene Logic’s plans for the future, its increased confidence and growing reach resulting from being part of Ocimum, and the rapidly changing genomics services market and competitive landscape.

Hencin: There’s certainly a shift away from the early target discovery days when people were searching madly for what kind of mechanistic things we could uncover with expression profiling. That’s still ongoing but it’s not the only thing. I think the shift has really been made to translational medicine. The question now is how can we take what we’ve learned in clinical and preclinical or tox studies and put it into the early phase clinical trials to develop markers to identify efficacy events or adverse events and more importantly to stratify the patients moving into trials to get a better population that’s going to save costs by not having as many non-responders. The biggest area of growth is in phase one and phase two clinical trials. I see the growth in areas where genomics can be applied in much larger trials and being able to have marker-based diagnostics that you will apply to your population to monitor it during the course the larger trials for both efficacy as well as adverse events. I think that the whole genomic ADME screening market is kind of a no brainer. You have to do this because there will be more of these markers that are almost mandated by FDA as well as pharmaceutical companies

Read the complete interview at the BioITworld website

Hello Pioneers,

Its been a while. We have been busy trying to make the gateway more useful for the community. We have been trying to reach out to Societies, regional councils, media and tech partners to spread the word around the Gateway. This will help making the Gateway a truly inclusive forum.

We have also finished interviewing a few promising Scientists and innovators who are working on ambitious broad application research themes in genomics. We will feature them in the gateway as soon as we have them ready to be posted.

What has also been keeping us busy are initial thoughts on an ambitious community virtual conference (perhaps mini-conference) on applied genomics.The dates and time are still up for discussion and so are the themes.

Here are some of the initial thoughts for sessions and themes:

If we were to break up the sessions into two parts spreading across two days to keep it light and engaging, here are some thoughts on potentially interesting sessions, if we can pull this agenda together.

Session I - OMICS Saturday (perhaps one or two invited ‘virtual’ speakers for each topic)

* Next-Gen Agriculture powered by Genomics
* Towards a Healthier World - Advancements in Food & Nutrition using Genomics
* Discovery Happens Here - Biodiscovery using genomics

Session II - Personalized Sunday (again perhaps one or two invited ‘virtual’ speakers for each topic)

· Who let these genes out? - Recent advancements and scope of different genome projects- 1000 genomes, personal genomics…
· Genomics of Aging- advancements and progress
· What is next in OMICS?

Its still very early into the planning, thoughts are still broad. We would love to hear from you on your thoughts and ideas. If you would like to contribute, participate, speak or suggest a speaker…that would be fantastic! Together we can make this happen.

cheers,

Ashwin

——————————

Genomic Pioneers Gateway

A Genelogic-Ocimum Biosolutions Initiative
email: ashw...@ocimumbio.com, asiv...@genelogic.com

www.genomicpioneers.com

——————————-